A Model to Predict Risk of Hyperkalemia in Patients with Chronic Kidney Disease Using a Large Administrative Claims Database

References

• United States Renal Data System. USRDS 2018 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2018. Available from: https://www.usrds.org/2018/view/Default.aspx. Accessed January 30, 2020.
   Google Scholar
• Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT. Health care utilization among patients with chronic kidney disease. Kidney Int. 2002;62(1):229–236. doi:10.1046/j.1523-1755.2002.00432.x
   PubMed Web of Science ®Google Scholar
• Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol. 2004;15(5):1300–1306. doi:10.1097/01.asn.0000125670.64996.bb
   PubMed Web of Science ®Google Scholar
• Wyld ML, Lee CM, Zhuo X, et al. Cost to government and society of chronic kidney disease stage 1–5: a national cohort study. Intern Med J. 2015;45(7):741–747. doi:10.1111/imj.12797
   Web of Science ®Google Scholar
• Golestaneh L, Alvarez PJ, Reaven NL, et al. All-cause costs increase exponentially with increased chronic kidney disease stage. Am J Manag Care. 2017;23(10 Suppl):S163–S172.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869. doi:10.1056/NEJMoa011161
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860. doi:10.1056/NEJMoa011303
   PubMed Web of Science ®Google Scholar
• The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349(9069):1857–1863. doi:10.1016/S0140-6736(96)11445-8
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 1998;352(9136):1252–1256. doi:10.1016/s0140-6736(98)04433-x
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Benini R, et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol. 1999;10(5):997–1006.
   Google Scholar
• Reaven NR, Funk SE, Bakris GL. The economics of renoprotective therapy in advanced diabetic kidney disease. Am J Pharm Benefits. 2014;6(6):e169–e176.
   Google Scholar
• Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585–592. doi:10.1056/NEJMra035279
   PubMed Web of Science ®Google Scholar
• Polson M, Lord TC, Kangethe A, et al. Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure. J Manag Care Spec Pharm. 2017;23(suppl4–a):S2–S9.
   Google Scholar
• Maggioni AP, Anker SD, Dahlström U, et al. Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15(10):1173–1184. doi:10.1093/eurjhf/hft134
   PubMed Web of Science ®Google Scholar
• Shirazian S, Grant CD, Mujeeb S, et al. Underprescription of renin–angiotensin system blockers in moderate to severe chronic kidney disease. N Am J Med Sci. 2015;349(6):510–515. doi:10.1097/MAJ.0000000000000475
   Web of Science ®Google Scholar
• Rassi AN, Cavender MA, Fonarow GC, et al. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol. 2013;61(1):35–40. doi:10.1016/j.jacc.2012.08.1019
   Web of Science ®Google Scholar
• Palmer BF. A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Dis. 2010;56(2):387–393. doi:10.1053/j.ajkd.2010.01.020
   Web of Science ®Google Scholar
• Latts LM, Reaven NL, Funk SE, McGaughey KJ, Oestreicher O, Adamson RT Hyperkalemia is prevalent in patients with cardiorenal comorbidities. Poster presented at: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting; May 16–20; 2015; Philadelphia, PA.
   Google Scholar
• Betts KA, Wooley JM, Mu F, Xiang C, Tang W, Wu EQ. The cost of hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385–393. doi:10.1016/j.ekir.2017.11.003
   PubMed Web of Science ®Google Scholar
• Rafique Z, Weir M, Onuigbo M, et al. Expert panel recommendations for the identification and management of hyperkalemia and role of patiromer in patients with chronic kidney disease and heart failure. J Manag Care Spec Pharm. 2017;23(4–a):S10–S20. doi:10.18553/jmcp.2017.23.4-a.s10
   Google Scholar
• Hernandez I, Zhang Y. Using predictive analytics and big data to optimize pharmaceutical outcomes. Am J Health Syst Pharm. 2017;74(18):1494–1500. doi:10.2146/ajhp161011
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. 2019 medicare-medicaid plan performance data technical notes; 2019. Available from: https://www.cms.gov/Medicare-Medicaid-Coordination/Medicare-and-Medicaid-Coordination/Medicare-Medicaid-Coordination-Office/FinancialAlignmentInitiative/Downloads/MMPPerformanceDataTechNotes.pdf. Accessed January 30, 2020.
   Google Scholar
• Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223–2233. doi:10.1001/jama.2014.15688
   PubMed Web of Science ®Google Scholar
• Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–387. doi:10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Hosmer DW, Lemeshow S. Model-building strategies and methods for logistic regression. In: Hosmer DW, Lemeshow S, editors. Applied Logistic Regression. 1st ed. New York: John Wiley & Sons; 1989:82–134.
   Google Scholar
• DeLong ER, DeLong DM, Clark-Pearson DL. Comparing the area under two or more correlated receiving operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845. doi:10.2307/2531595
   PubMed Web of Science ®Google Scholar
• Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36. doi:10.1148/radiology.143.1.7063747
   PubMed Web of Science ®Google Scholar
• CKD United States Renal Data System. End-stage renal disease (ESRD) in the United States. In: USRDS 2018 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; 2018. Available from: https://www.usrds.org/2018/view/Default.aspx. Accessed April 30, 2020.
   Google Scholar
• Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 suppl 1):S1–S290.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2:337–414.
   Web of Science ®Google Scholar
• American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(suppl1):S124–S138. doi:10.2337/dc19-S011
   Web of Science ®Google Scholar
• HHS launches President Trump’s Advancing American Kidney Health Initiative. News release. US department of health and human services; 2019. Available from: https://www.hhs.gov/about/news/2019/07/10/hhs-launches-president-trump-advancing-american-kidney-health-initiative.html. Accessed January 30, 2019.
   Google Scholar
• US Department of Health and Human Services. Advancing American kidney health; 2019. Available from: https://aspe.hhs.gov/pdf-report/advancing-american-kidney-health. Accessed January 30, 2019.
   Google Scholar
• Johnson ES, Weinstein JR, Thorp ML, et al. Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiol Drug Saf. 2010;19(3):266–272. doi:10.1002/pds.1923
   Web of Science ®Google Scholar
• Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project. J Am Heart Assoc. 2017;6(7):pii:e005428. doi:10.1161/JAHA.116.005428
   Web of Science ®Google Scholar
• Urbine TF, Schwenke DC, Wu WC, Dev S. ICD9 coding of hyperkalemia greatly underestimates incidence of lab-defined hyperkalemia in veterans with heart failure. J Card Fail. 2013;19(8):S32. doi:10.1016/j.cardfail.2013.06.107
   Web of Science ®Google Scholar
• Fitch K, Woolley JM, Engel T, Blumen H. The clinical and economic burden of hyperkalemia on Medicare and commercial payers. Am Health Drug Benefits. 2017;10(4):202–210.
   PubMed Web of Science ®Google Scholar
• Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372(3):222–231. doi:10.1056/NEJMoa1411487
   PubMed Web of Science ®Google Scholar
• Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17(10):1057–1065. doi:10.1002/ejhf.402
   PubMed Web of Science ®Google Scholar
• Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211–221. doi:10.1056/NEJMoa1410853
   PubMed Web of Science ®Google Scholar
• Weir MR, Bushinsky DA, Benton WW, et al. Effect of patiromer on hyperkalemia recurrence in older chronic kidney disease patients taking RAAS inhibitors. Am J Med. 2018;131(5):e3. doi:10.1016/j.amjmed.2017.11.011
   Web of Science ®Google Scholar
• Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820–828. doi:10.1093/eurheartj/ehq502
   PubMed Web of Science ®Google Scholar